CRLX101 Plus Bevacizumab in Advanced RCC

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Abramson Cancer Center at Penn Medicine
Study ID
NCT01625936
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • CRLX101 (Cerulean) — DRUG
    CRLX101 is an innovative tumor-targeting nanopharmaceutical.
  • Bevacizumab — DRUG

Study Details

This is a Phase 1b, dose escalation study of the investigational agent, CRLX101, given in combination with Bevacizumab in patients with advanced renal cell carcinoma. The purpose of this study is to determine the initial safety and effectiveness of this agent in combination with Bevacizumab. The investigators are also trying to determine the best dose level of CRLX101 to give in combination with bevacizumab. About 22 subjects will be enrolled in this study at the University of Pennsylvania.

Key Dates

First listed
Jun 22, 2012
Start date
Jun 30, 2012
Status verified
Aug 2018
Primary completion
Jul 1, 2017
Completion
Jul 16, 2018

Study Design

Enrollment
22 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Number of Adverse Events

Locations (1)

FacilityCityStateZIPSite coordinators
Abramson Cancer Center of the University of PennsylvaniaPhiladelphiaPennsylvania19104-

Find similar trials in Philadelphia, PA

By condition
Kidney cancer
By specialty
OncologyUrology
By research site
Abramson Cancer Center of the University of Pennsylvania· Philadelphia, PA

Related Studies